Sugi Predict

Sugi Predict / Targets / EHMT1

EHMT1

Histone-lysine N-methyltransferase EHMT1 · Q9H9B1 · EHMT1 on Sugi Atlas →

22,289 patent compounds predicted against EHMT1, 13,654 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL199314 SCHEMBL199314 0.60 15/20
SCHEMBL1428017 SCHEMBL1428017 0.54 8/20
SCHEMBL199299 SCHEMBL199299 0.51 8/20
SCHEMBL899551 SCHEMBL899551 0.62 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL900295) 0.61 7/20
SCHEMBL424718 SCHEMBL424718 0.52 7/20
SCHEMBL429383 SCHEMBL429383 0.52 7/20
SCHEMBL429384 SCHEMBL429384 0.52 7/20
SCHEMBL1427882 SCHEMBL1427882 0.63 6/20
SCHEMBL1427619 SCHEMBL1427619 0.62 6/20
SCHEMBL1401245 SCHEMBL1401245 0.44 6/20
SCHEMBL996743 SCHEMBL996743 0.78 5/20
SCHEMBL1430299 SCHEMBL1430299 0.65 5/20
SCHEMBL430392 SCHEMBL430392 0.47 5/20
Disulfiram Disulfiram (SCHEMBL27213) 1.00 4/20
SCHEMBL76857 SCHEMBL76857 1.00 4/20
SCHEMBL941769 SCHEMBL941769 0.62 4/20
SCHEMBL150725 SCHEMBL150725 0.60 4/20
SCHEMBL1093486 SCHEMBL1093486 0.56 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1157944) 0.56 4/20

Clinical trials — most relevant to EHMT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
MR Antagonist and LSD1 PHASE4ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EHMT1 binder may also engage these)

ProteinNameSimilarity
Q5DW34 — 1.000 Q5DW34 →
Q811D2 — 1.000 Q811D2 →
P10244 — 0.999 P10244 →
Q9Z148 — 0.999 Q9Z148 →
Q90ZS6 — 0.999 Q90ZS6 →
EHMT2 Histone-lysine N-methyltransferase EHMT2 0.999 landscape →
O54963 — 0.998 O54963 →
P46200 — 0.998 P46200 →
O43310 — 0.998 O43310 →
Q9NYI0 — 0.997 Q9NYI0 →
Q2PFD7 — 0.997 Q2PFD7 →
KDM3B Lysine-specific demethylase 3B 0.997 landscape →
E9Q555 — 0.997 E9Q555 →
Q9UPV7 — 0.997 Q9UPV7 →
Q76I79 — 0.997 Q76I79 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.997 landscape →
F1MJR8 — 0.996 F1MJR8 →
Q5TKR9 — 0.996 Q5TKR9 →
Q92539 — 0.996 Q92539 →
Q9JKY3 — 0.996 Q9JKY3 →
Q9Z2U2 — 0.996 Q9Z2U2 →
Q6KAQ7 — 0.996 Q6KAQ7 →
Q5SPL2 — 0.996 Q5SPL2 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.996 landscape →
Q64318 — 0.996 Q64318 →
Q8IUE1 — 0.996 Q8IUE1 →
Q62947 — 0.996 Q62947 →
Q63553 — 0.996 Q63553 →
Q3U285 — 0.996 Q3U285 →
Q60542 — 0.996 Q60542 →